CTMX - CIK 0001501989
The table below shows CytomX Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.67M | $38.05M | $17.17M | $193.65M | $205.53M | $191.86M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $2.01M | $3.10M | $3.43M | $35.99M | $790.00K | $798.00K |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $143.92M |
| $107.31M |
| $182.94M |
| $237.10M |
| $310.30M |
| $324.01M |
| Property, plant & equipment | $1.30M | $2.47M | $3.96M | $5.07M | $5.96M | $6.95M |
| Goodwill | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K |
| Total assets | $151.57M | $120.53M | $201.79M | $260.89M | $339.41M | $358.66M |
| Accounts payable | $1.30M | $1.09M | $1.46M | $2.81M | $2.82M | $3.00M |
| Total current liabilities | $46.62M | $85.77M | $155.91M | $152.61M | $106.32M | $100.92M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $52.56M | $120.99M | $249.24M | $346.64M | $250.03M | $308.86M |
| Retained earnings | -$711.95M | -$691.58M | -$723.45M | -$722.88M | -$623.56M | -$450.12M |
| Total equity | $99.01M | -$456.00K | -$47.45M | -$85.75M | -$459.00K | $49.80M |